Keros Therapeutics, Inc.
KROS · XNASCIK 1664710fmd_1HPRBJZQA2STSE1RKTHBKW05ZQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
AI-written
A model wrote this from the company's own SEC filings and our standardized facts. It is not reported fact, not an analyst's estimate, not a rating and not investment advice. Every claim shows what it rests on.
Loading